10-Q: Profound Medical Q3 2025: Revenue Up, Cash Down, Debt Risk

Profound Medical Corp. reported significant revenue growth in Q3 2025, but faces a material uncertainty regarding its ability to continue as a going concern due to declining cash and projected debt covenant breach.

Summary

• Revenue for the three months ended September 30, 2025, increased by 87% to $5,289 thousand, compared to $2,832 thousand in the prior year.
• Gross profit for the three months ended September 30, 2025, rose by 120% to $3,931 thousand, with gross margin improving to 74% from 63%.
• Net loss for the three months ended September 30, 2025, improved by 15% to $7,977 thousand, down from $9,365 thousand in the same period last year.
• For the nine months ended September 30, 2025, revenue increased by 56% to $10,121 thousand, compared to $6,504 thousand in the prior year.
• Net loss for the nine months ended September 30, 2025, worsened by 50% to $34,395 thousand, up from $22,869 thousand in the prior year.
• Cash balance significantly decreased to $24,826 thousand as of September 30, 2025, from $54,912 thousand at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $31,641 thousand, an increase from $17,574 thousand in the prior year.
• The company has an accumulated deficit of $279,566 thousand as of September 30, 2025.
• Management believes current cash balances are insufficient to fund planned business operations for the next year, raising substantial doubt about the company's ability to continue as a going concern.
• The company projects a violation of a financial covenant under the CIBC Credit Agreement by June 30, 2026, which could lead to the outstanding debt being declared immediately due and payable.

Sentiment

Score: 3

Explanation: While revenue growth and Q3 net loss improvement are positive, the severe liquidity issues, explicit going concern warning, significant cash burn, and projected debt covenant breach create substantial financial instability and risk, outweighing operational improvements.

Positives

• Revenue for the three months ended September 30, 2025, increased by 87% to $5,289 thousand, driven by higher capital sales and recurring revenue in the United States.
• Gross profit for the three months ended September 30, 2025, increased by 120% to $3,931 thousand, with gross margin improving to 74% due to higher efficiency rates in manufacturing and a favorable product mix.
• Net loss for the three months ended September 30, 2025, decreased by 15% to $7,977 thousand, and basic and diluted loss per common share improved by 32% to $0.26.
• The TULSA-PRO system is CE marked, Health Canada approved, and 510(k) cleared by the U.S. FDA, indicating strong regulatory standing.
• Sonalleve is CE marked for uterine fibroids and palliative pain treatment of bone metastases, and has FDA approval under a Humanitarian Device Exemption for osteoid osteoma, expanding market reach.

Negatives

• The company has historically experienced recurring losses from operations and incurred an accumulated deficit of $279,566 thousand through September 30, 2025.
• Cash balance significantly decreased to $24,826 thousand as of September 30, 2025, from $54,912 thousand at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, increased to $31,641 thousand from $17,574 thousand in the prior year, indicating increased cash burn.
• Net loss for the nine months ended September 30, 2025, worsened by 50% to $34,395 thousand, and basic and diluted loss per common share increased by 21% to $1.14.
• Management believes current cash balances are not sufficient to finance all planned business operations over the next year, raising substantial doubt about the company's ability to continue as a going concern.
• The company projects a violation of a financial covenant under the CIBC Credit Agreement by June 30, 2026, which could result in the outstanding debt being declared immediately due and payable.
• A material weakness in internal control over financial reporting related to revenue recognition (ASC 606) was identified for the year ended December 31, 2024, with remediation efforts ongoing.

Risks

• There is substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months.
• Inability to obtain additional financing on acceptable terms could force the company to curtail development programs, cut operating costs, or even liquidate business interests.
• Projected breach of a financial covenant under the CIBC Credit Agreement by June 30, 2026, could lead to the outstanding debt obligation being declared immediately due and payable.
• Failure to negotiate a covenant waiver or replace/refinance existing debt could materially adversely impact financial results and the trading price of common shares.
• The material weakness in internal control over financial reporting related to revenue recognition could result in misstatements of financial statements if not fully remediated.
• The company depends on the successful development and marketing of its products and the ability to raise additional financing to support these activities.

Future Outlook

Management believes current cash balances will not be sufficient to fund planned business operations for the next 12 months and intends to seek additional financing from investors or other sources of capital. The company anticipates increased expenses due to continued commercialization of TULSA-PRO and Sonalleve and expects to continue substantial investments in R&D and sales expansion. Future compliance with debt covenants is dependent on achieving certain revenue, EBITDA, and unrestricted cash levels, with a projected breach by June 30, 2026.

Management Comments

• Management believes that current cash balances as of September 30, 2025, will not be sufficient to finance all of its planned business operations over the next year.
• The company intends to seek additional financing from investors or other sources of capital in order to fund its operations and activities over the next year.
• If a waiver cannot be obtained from CIBC for the projected covenant violation, the company will have sufficient unrestricted cash to repay the total remaining outstanding debt obligation that may become due.

Industry Context

Profound Medical operates in the competitive medical device industry, specializing in image-guided ablation procedures. The company's focus on platform technologies like TULSA-PRO and Sonalleve positions it within the growing market for minimally invasive therapeutic systems. The continued investment in R&D, particularly for clinical trials like CAPTAIN, and efforts to increase compatibility with MRI scanners, reflect the industry's drive towards technological advancement and broader clinical application. The hybrid revenue model for TULSA-PRO in the US and capital sales model for Sonalleve overseas indicate adaptation to different market dynamics and healthcare systems.

Corporate Governance

Stakeholder Impact

• Shareholders face significant risk of dilution from potential future equity financings and a material adverse effect on the trading price of common shares due to going concern issues and debt covenant breaches.
• Employees may benefit from increased headcount and share-based compensation, but the company's financial instability could pose future employment risks.
• Customers may benefit from continued product development and commercialization of TULSA-PRO and Sonalleve, but the company's long-term viability is uncertain.
• Creditors (specifically CIBC) face increased risk due to the projected debt covenant breach, potentially leading to accelerated debt repayment.

Next Steps

• Seek additional financing from investors or other sources of capital to fund operations and activities over the next year.
• Continue remediation efforts for the material weakness in internal control over financial reporting, with completion expected during 2025.
• Monitor and manage compliance with financial covenants under the CIBC Credit Agreement, potentially seeking waivers or amendments if a projected breach occurs.
• Continue commercialization of the TULSA-PRO system in the United States and globally, and the Sonalleve system globally.
• Continue development of the TULSA-PRO and Sonalleve systems, including investments in clinical trials (e.g., CAPTAIN trial) and R&D initiatives.

Key Dates

Recommendation

Despite strong revenue growth in the quarter, the company's explicit 'going concern' warning, significant cash burn, and projected breach of a debt covenant by mid-2026 present an existential threat to its operations. The substantial accumulated deficit and reliance on future financing, which is not assured, indicate severe liquidity risk. While management expresses confidence in repaying debt if a waiver isn't obtained, this scenario itself highlights a precarious financial position. The fundamental risks far outweigh the operational positives, making the stock a high-risk investment with significant downside potential.

Keywords

Medical device, TULSA-PRO, Sonalleve, Prostate cancer, Uterine fibroids, Ablation therapy, MRI-guided ultrasound, Financial results, Q3 2025, SEC filing, Going concern, Debt covenant, Capital raise, Liquidity, Operating loss